CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 6376659
• 负责人: MARY ELLEN TAPLIN
• 金额: $ 9.68万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-09 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6376659
• 关键词: Hodgkin's disease; SCID mouse; androgen receptor; blood banks; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cancer risk; cell cycle; cell growth regulation; chemoprevention; clinical research; clinical trials; colony stimulating factor; colorectal neoplasms; combination cancer therapy; cooperative study; coping; cytogenetics; data management; esophagus neoplasm; female; gastrointestinal neoplasms; gene therapy; glioma; human subject; human therapy evaluation; leukemia; lymphedema; lymphoma; male; mammography; metastasis; minimal residual disease; mitoxantrone; molecular oncology; multidrug resistance; neoplasm /cancer; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nonHodgkin's lymphoma; oncogenes; oncology nursing; prognosis; prostate neoplasms; quality of life; smoking cessation; statistics /biometry; tissue resource /registry

DESCRIPTION (adapted from the applicant's abstract): Since its inception in 1993, the University of Massachusetts Cancer Center has sought to elucidate new insights into normal and cancer cell biology. Investigators based at U Mass are beginning to translate this knowledge into clinical correlative studies and therapeutic approaches through the CALGB. For example, Dr. Mary-Ellen Taplin has described specific androgen receptor gene mutations that may target more effective treatments for hormone independent prostate cancer. These initial studies constitute one of the funded Correlative Science Studies through the CALGB and comprises one of the CALGB Core Labs. Based on our experience and substantial base in hematopoietic cell biology, a major focus of the U Mass Cancer Center has been in transplantion biology. Efforts have centered on (1) determining factors that enhance engraftment, (2) the development of entirely new transplant models using minimal myeloablation, (3) cord blood transplantation, (4) NOD-SCID preclinical transplant models to detect minimal residual disease, and (5) gene therapy approaches such as MDR1 transfer into normal hematopoietic stem cells. Many principles of hematopoietic stem cell biology "are now being applied to solid organ systems, with investigators at U Mass evaluating growth characteristics of both normal and neoplastic cells by defining the malignant stem cell" in solid tumor systems and defining autocrine and paracrine loop pathways of growth control. Stem cell "studies in breast cancer, prostate cancer, and glioblastoma" are ongoing and may provide important clinical correlative studies as companion studies to CALGB treatment protocols. Our Group Activities and Scientific contributions have increased significantly in the past four years. U Mass investigators in CALGB have contributed substantially to activities in Transplant, Breast Cancer, Prostate Cancer, Surgery, and Gastrointestinal Cancer. Administrative contributions through the Audit committee and other ad hoc committees have been substantial. Major efforts have led to improvement in accrual to Group Studies and improvement in the quality of data submitted on CALGB clinical trials.

描述（改编自申请人的摘要）：自成立以来 1993 年，马萨诸塞大学癌症中心试图阐明 对正常细胞和癌细胞生物学的新见解。 调查人员驻扎在U Mass 开始将这些知识转化为临床相关知识 通过 CALGB 进行研究和治疗方法。 例如，博士。 Mary-Ellen Taplin 描述了特定的雄激素受体基因突变 可能针对激素非依赖性前列腺的更有效治疗 癌症。 这些初步研究构成了资助的相关研究之一 通过 CALGB 开展科学研究，并由 CALGB 核心实验室之一组成。 基于我们在造血细胞生物学方面的经验和扎实的基础， 麻省大学癌症中心的一个主要重点是移植生物学。 努力集中在（1）确定增强植入的因素， (2) 使用最少的技术开发全新的移植模型 清髓术，(3) 脐带血移植，(4) NOD-SCID 临床前 检测微小残留病的移植模型，以及（5）基因治疗 MDR1 等方法转移到正常造血干细胞中。 许多 造血干细胞生物学原理“现在被应用于 实体器官系统，麻省大学的研究人员评估生长情况 通过定义正常细胞和肿瘤细胞的特征 实体瘤系统中的恶性干细胞并定义自分泌和 生长控制的旁分泌循环途径。 乳腺干细胞研究 癌症、前列腺癌和胶质母细胞瘤”正在进行中，可能会提供 作为 CALGB 伴随研究的重要临床相关研究 治疗方案。 我们的团体活动和科学贡献 过去四年显着增加。 U Mass调查员 CALGB 对移植、乳房等领域的活动做出了重大贡献 癌症、前列腺癌、手术和胃肠癌。 通过审计委员会和其他临时机构提供的行政捐款 委员会的规模很大。 重大努力已带来改善 小组研究的累积和提交数据质量的提高 CALGB 临床试验。